Myriad Genetics | MYGN - Operating Profit


Myriad Genetics reported $-23.3M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Agilent USD 443M 66M Sep/2025
Becton, Dickinson and Co. USD 826M 153M Sep/2025
Bio-Rad Laboratories USD 77.1M 53.4M Jun/2025
Bruker USD 83.9M 72M Sep/2025
Danaher USD 1.5B 348M Dec/2025
Exact Sciences USD -25M 22.85M Sep/2025
Hologic USD 237M 16M Dec/2025
Illumina USD 250M 5M Sep/2025
J&J USD 5.59B 1.81B Dec/2025
Mettler Toledo International USD 294.2M 28.49M Sep/2025
Myriad Genetics USD -23.3M 10.8M Sep/2025
Quest Diagnostics USD 386M 52M Sep/2025
Quidel USD -704.8M 703M Sep/2025
Repligen USD 12.68M 6.72M Sep/2025
Revvity USD 98.34M 8.63M Sep/2025
Standard Biotools USD -23.47M 230K Sep/2025
Thermo Fisher Scientific USD 2.3B 226M Dec/2025
Veracyte USD 23.11M 8.8M Sep/2025
Waters USD 192.11M 3.9M Sep/2025